← boardnext 2026-08
CRIS
Curis, Inc.distress 8/10 · high distress / dilution risk$5.03+2%today-87% from 52w high
Oncology 2
Lead: Chronic Lymphocytic Leukemia · target IRAK4 · est. market ~$15B (approx, global)
Revenue
pre-revenue
Liquidity
$15M
Runway
0.5 yrs
Shares 1y
+212%
Price & events
-72.1% over 6M
CatalystRating changeDilutionFinancingdashed = today
+1.8%
1D
+1.0%
1W
-30.1%
1M
-58.8%
3M
-73.2%
6M
-86.2%
1Y
-96.0%
2Y
-99.8%
5Y
-99.9%
All
Overview
- Market Cap
- $196.06M
- Volume
- 15.47K
- 52 Week Range
- $4.20 – $37.60
- Total Shares
- 38.98M
- Float Shares
- 1.38M
- Short %
- 9.11%
- % Held by Insiders
- 8.03%
- % Held by Institutions
- 40.50%
- RVOL
- 0.05x
- Beta
- 3.07
Pipeline stages · 1 programs
Emavusertib, Zanubrutinib
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved
Pipeline · 3 trials · 2 upcoming
| Readout | Phase | Drug | Indication | Enroll | Status |
|---|---|---|---|---|---|
| 2026-08 Estimated 50% readout ~2026-09-15 | Phase 1/2 | Emavusertib, Ibrutinib | Relapsed Hematologic Malignancy, Refractory Hematologic Malignancy, Relapsed Primary Central Nervous System Lymphoma, Refractory Primary Central Nervous System Lymphoma | 152 | recruiting |
| 2027-11 Estimated 50% readout ~2027-12-16 | Phase 2 | Emavusertib, Zanubrutinib | Chronic Lymphocytic Leukemia, B-cell Malignancies | — | recruiting |
| 2026-04-01 | Phase 1/2 | Emavusertib, Venetoclax | Acute Myelogenous Leukemia, Myelodysplastic Syndrome | 366 | suspended |
Catalyst news & presentations · 2
- 2026-08-11Estimated 45%earningsEarningsEarnings releaseyahoo
- 2025-11-06partnershipErivedge · Sold Curis Royalty LLC, including Erivedge license and royalty rights, to Oberland-managed entity for $2.5M upfront and liability release.SEC 8-K
Approved drugs (0)
- none — clinical-stage
Capital structure — dilution & financing
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to ProWall St ratings
strong buy · target $14 (+178% upside) · 3 analysts
- 2026-03-20HC Wainwright & Co.Buy
- 2025-03-31HC Wainwright & Co.Buy
- 2024-12-10HC Wainwright & Co.Buy
- 2024-11-15HC Wainwright & Co.Buy
- 2024-11-01HC Wainwright & Co.Buy
- 2024-08-01HC Wainwright & Co.Buy
Competitors — IRAK4
- none identified
Recent news
- 2026-07-23CRIS Q2'26 Earnings: revenue estimate is 1.00M USD - TradingView
- 2026-07-22Curis Strengthens Oncology Pipeline Outlook With Strong TakeAim Lymphoma Response Rates - Benzinga
- 2026-07-22Curis Q2 2026: Updated Clinical Data for Emavusertib Trials - grafa.com
- 2026-07-22Curis shares surge after updated emavusertib data strengthens clinical outlook (NASDAQ:CRIS) - Yahoo Finance
- 2026-07-22Curis stock jumps 11% on positive emavusertib trial data - Investing.com UK
- 2026-07-22Curis reports updated trial data for emavusertib in lymphoma By Investing.com - Investing.com South Africa
- 2026-07-22Curis reports updated trial data for emavusertib in lymphoma By Investing.com - Investing.com UK
- 2026-07-22Curis Announces Positive Emavusertib Update - PR Newswire
Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.